DOCSLIB.ORG

Advantages of Hyaluronic Acid and Its Combination with Other Bioactive Ingredients in Cosmeceuticals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advantages of Hyaluronic Acid and Its Combination with Other Bioactive Ingredients in Cosmeceuticals molecules Review Advantages of Hyaluronic Acid and Its Combination with Other Bioactive Ingredients in Cosmeceuticals Anca Maria Juncan 1,2,3,* , Dana Georgiana Moisă 3,*, Antonello Santini 4 , Claudiu Morgovan 3,* , 3 3 1 Luca-Liviu Rus , Andreea Loredana Vonica-T, incu and Felicia Loghin 1 Department of Toxicology, Faculty of Pharmacy, “Iuliu Hat, ieganu” University of Medicine and Pharmacy, 6 Pasteur Str., 400349 Cluj-Napoca, Romania; fl[email protected] 2 SC Aviva Cosmetics SRL, 71A Kövari Str., 400217 Cluj-Napoca, Romania 3 Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga Str., 550169 Sibiu, Romania; [email protected] (L.-L.R.); [email protected] (A.L.V.-T, .) 4 Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy; [email protected] * Correspondence: [email protected] or [email protected] (A.M.J.); [email protected] (D.G.M.); [email protected] (C.M.) Abstract: This study proposes a review on hyaluronic acid (HA) known as hyaluronan or hyaluronate and its derivates and their application in cosmetic formulations. HA is a glycosaminoglycan consti- tuted from two disaccharides (N-acetylglucosamine and D-glucuronic acid), isolated initially from the vitreous humour of the eye, and subsequently discovered in different tissues or fluids (especially Citation: Juncan, A.M.; Mois˘a,D.G.; in the articular cartilage and the synovial fluid). It is ubiquitous in vertebrates, including humans, and Santini, A.; Morgovan, C.; Rus, L.-L.; it is involved in diverse biological processes, such as cell differentiation, embryological development, Vonica-T, incu, A.L.; Loghin, F. inflammation, wound healing, etc. HA has many qualities that recommend it over other substances Advantages of Hyaluronic Acid and used in skin regeneration, with moisturizing and anti-ageing effects. HA molecular weight influences Its Combination with Other Bioactive its penetration into the skin and its biological activity. Considering that, nowadays, hyaluronic Ingredients in Cosmeceuticals. acid has a wide use and a multitude of applications (in ophthalmology, arthrology, pneumology, Molecules 2021, 26, 4429. https:// rhinology, aesthetic medicine, oncology, nutrition, and cosmetics), the present study describes the doi.org/10.3390/molecules26154429 main aspects related to its use in cosmetology. The biological effect of HA on the skin level and its potential adverse effects are discussed. Some available cosmetic products containing HA have Academic Editors: María De La Luz Cádiz-Gurrea, Antonio been identified from the brand portfolio of most known manufacturers and their composition was Segura-Carretero and David evaluated. Further, additional biological effects due to the other active ingredients (plant extracts, Arráez-Román vitamins, amino acids, peptides, proteins, saccharides, probiotics, etc.) are presented, as well as a description of their possible toxic effects. Received: 7 June 2021 Accepted: 20 July 2021 Keywords: hyaluronic acid; cosmeceuticals; biological activity; skin health; moisturising effect; Published: 22 July 2021 anti-ageing effect; bioactive compounds; molecular weight; hyaluronan derivates Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- 1. Introduction iations. Hyaluronic acid (HA) is a polysaccharide belonging to the glycosaminoglycans, made up of disaccharide units constituted of N-acetylglucosamine and D-glucuronic acid (Figure1) . It is a component of the connective, epithelial, and neural tissues and it represents a substantial constituent of the extracellular matrix (ECM) [1–6]. HA was Copyright: © 2021 by the authors. discovered for the first time in the vitreous humour of the eye in 1934, and in 1964 it was Licensee MDPI, Basel, Switzerland. synthesized in vitro [7–9]. HA has a wide range of molecular weights ranging from 2 × 105 This article is an open access article to 107 Da [10–13]. The HA average molecular weight can influence its physico-chemical distributed under the terms and properties [3,14]. conditions of the Creative Commons Among the many biological effects, HA is involved in cell differentiation, embry- Attribution (CC BY) license (https:// ological development, inflammation, wound healing, viscoelasticity, etc. [15]. As it has creativecommons.org/licenses/by/ been observed, the molecular mass and the mode of its synthesis or degradation define 4.0/). Molecules 2021, 26, 4429. https://doi.org/10.3390/molecules26154429 https://www.mdpi.com/journal/molecules Molecules 2021, 26, 4429 2 of 43 the HA biological effects [3,16,17]. By a passive mechanism, high molecular weight HA (HMW-HA) permits the tissue hydration, contributes to the osmotic balance, and stabilizes the ECM structure. On the other hand, HA interacts with different receptor binding pro- teins, and its molecular weight can influence the receptor affinity or its uptake by the cells, leading to opposite effects. For example, HMW-HA inhibits the cell growth (angiogenetic activity) and protects the articular cartilage due to its lubrication properties. Low molecular weight HA (LMW-HA) has angiogenetic activity and can induce tumor progression or presents pro-inflammatory activity [15,16]. Thus, the biological activity of HA is due to its binding to different receptors. For example, the binding HA-CD44 transmembrane receptor mediates cell adhesion and migration in many physiological or pathophysiolog- ical processes: (a) angiogenesis; (b) ECM structure (linking the HA with cytoskeleton); (c) inflammation (upregulation of the receptors overexpresses the interleukin-1); (d) wound healing; (e) malignant tumors (e.g., pancreatic, breast, lung, etc.). The CD-168 receptor (Receptor for Hyaluronan-Mediated Motility, RHAMM) localized on the cell surface has an important relevance in cell migration. When the receptor is situated intracellularly, it affects the activity of the mitotic spindle. As a result, the HA-RHAMM links can influence the inflammation and tissue repair processes. The HARE (Hyaluronan Receptor for En- docytosis) receptors modulate the glycosaminoglycans clearance. The lymph absorption of HA, implicitly the HA turnover, is controlled by LYVE1 (Lymphatic Vessel Endothelial Hyaluronan receptor-1). As a result, HA-LYVE1 interaction influences the tissue biome- chanical properties, including its hydration. Referring to the HA interaction with TLRs (Toll-Like Receptor), it is noticed that LMW-HA has an inflammatory effect, because of its agonist activity on TLR-2 and TLR-4. On the other hand, a high mass of HA decreases the Molecules 2021, 26, x FOR PEER REVIEW 2 of 40 binding capacity to the receptors, forming a dense coat around the cell and covering the receptor surface [15,16,18,19]. FigureFigure 1. 1. ChemicalChemical structure structure of of hyaluronic hyaluronic acid acid (HA). (HA). AmongNowadays, the many there arebiological a lot of studieseffects, conductedHA is involved in order in tocell elucidate differentiation, the mechanism embryo- of logicalaction anddevelopment, the biosynthetic inflammation, pathways ofwound HA, orhealing, to optimize viscoelasticity, its biotechnological etc. [15]. production, As it has beenin order observed, to synthesize the molecular derivatives mass with and superior the mode properties of its synthesis and to improveor degradation its therapeutic define theutilization HA biological [16]. effects [3,16,17]. By a passive mechanism, high molecular weight HA (HMW-HA)The list permits of substances the tissue that hydration, are restricted cont orributes prohibited to the in osmotic the EU balance, for use in and cosmetic stabi- lizesproducts the ECM does structure. not include On hyaluronic the other acid hand, and HA sodium interacts hyaluronate with different (NaHA). receptor As an example,binding proteins,using hyaluronic and its molecular acid, sodium weight hyaluronate, can influence or potassium the receptor hyaluronate affinity or (KHA) its uptake in cosmetics by the cells,is not leading restricted to opposite in Japan [effects.20]. For example, HMW-HA inhibits the cell growth (angio- geneticSome activity) studies and realized protects by the the articular Cosmetic ca Ingredientrtilage due Review to its lubrication (CIR) experts properties. panel, based Low molecularon the application weight HA of cosmetic(LMW-HA) HA has in variousangiogenetic concentrations, activity and showed can induce acute, tumor short-term, pro- gressionor chronic or toxicitypresents [ 20pro-inflammatory]. Additionally, someactivity side [15,16]. tolerable Thus, effects the biological (scaling, erythema,activity of HA and pruritus) were observed, after the use of a topical product with hyaluronic acid (0.01%), is due to its binding to different receptors. For example, the binding HA-CD44 transmem- hydroquinone (4%), and glycolic acid (10%) for melasma treatment [4]. Subsequently, brane receptor mediates cell adhesion and migration in many physiological or pathophys- HA and NaHA can be nebulized and used in cosmetic products which can be applied as iological processes: (a) angiogenesis; (b) ECM structure (linking the HA with cytoskele- ton); (c) inflammation (upregulation of the receptors overexpresses the interleukin-1); (d) wound healing; (e) malignant tumors (e.g., pancreatic, breast, lung, etc.). The CD-168 re- ceptor (Receptor for Hyaluronan-Mediated Motility, RHAMM) localized on the cell sur- face has an important relevance in cell migration.
Load more

Recommended publications
  • Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis
    Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mösges, Carlos E. Baena-Cagnani, and Desiderio Passali Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Allergy.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board William E. Berger, USA Alan P. Knutsen, USA Fabienne Ranc, France Kurt Blaser, Switzerland Marek L. Kowalski, Poland Anuradha Ray, USA Eugene R. Bleecker, USA Ting Fan Leung, Hong Kong Harald Renz, Germany JandeMonchy,TheNetherlands Clare M Lloyd, UK Nima Rezaei, Iran Frank Hoebers, The Netherlands Redwan Moqbel, Canada Robert P. Schleimer, USA StephenT.Holgate,UK Desiderio Passali, Italy Massimo Triggiani, Italy Sebastian L. Johnston, UK Stephen P. Peters, USA Hugo Van Bever, Singapore Young J. Juhn, USA David G. Proud, Canada Garry Walsh, United Kingdom Contents Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis,RalphMosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Volume 2014, Article ID 416236, 2 pages Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity (Septoplasty, Simple Ethmoid Sinus Surgery, and Turbinate Surgery), Ina Gouteva, Kija Shah-Hosseini, and Peter Meiser Volume 2014, Article ID 635490, 10 pages The Effectiveness of Acupuncture Compared to Loratadine in Patients Allergic to House Dust ,Mites Bettina Hauswald, Christina Dill, Jurgen¨ Boxberger, Eberhard Kuhlisch, Thomas Zahnert, and Yury M.
    [Show full text]
  • Methyl Vinyl Ketone Mvk
    METHYL VINYL KETONE MVK CAUTIONARY RESPONSE INFORMATION 4. FIRE HAZARDS 7. SHIPPING INFORMATION 4.1 Flash Point: 30°F O.C. 20°F C.C. 7.1 Grades of Purity: 98.5+% Common Synonyms Liquid Colorless to light yellow Strong irritating 4.2 Flammable Limits in Air: 2.1% 15.6% 7.2 Storage Temperature: Cool ambient 3-Buten-2-one odor 4.3 Fire Extinguishing Agents: Dry 7.3 Inert Atmosphere: No requirement chemical, alcohol foam, carbon dioxide 7.4 Venting: Pressure-vacuum Mixes with water. Irritating vapor is produced. 4.4 Fire Extinguishing Agents Not to Be Used: Water may be ineffective. 7.5 IMO Pollution Category: Currently not available Evacuate. 4.5 Special Hazards of Combustion 7.6 Ship Type: Currently not available KEEP PEOPLE AWAY. AVOID CONTACT WITH LIQUID. Products: Not pertinent 7.7 Barge Hull Type: Currently not available Avoid inhalation. 4.6 Behavior in Fire: Vapor is heavier than Wear rubber overclothing (including gloves). air and may travel a considerable Shut off ignition sources. Call fire department. 8. HAZARD CLASSIFICATIONS distance to a source of ignition and flash Stay upwind. Use water spray to ``knock down'' vapor. back. At elevated temperatures (fire 8.1 49 CFR Category: Flammable liquid Notify local health and pollution control agencies. conditions) polymerization may take Protect water intakes. 8.2 49 CFR Class: 3 place in containers, causing violent 8.3 49 CFR Package Group: II rupture. Unburned vapors are very FLAMMABLE. irritating. 8.4 Marine Pollutant: No Fire Containers may explode in fire. 8.5 NFPA Hazard Classification: Flashback along vapor trail may occur.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Scabies in Healthcare Facilities
    Scabies in Healthcare Facilities Tammra L. Morrison, RN BSN Healthcare Associated Infections Coordinator Communicable Disease Branch, Epidemiology Section December 9, 2016 Symptoms • In a person who has never had scabies: • May take 4-6 weeks for symptom onset • In a person who has had scabies in the past: • Symptoms may start in 1-4 days • May be spread PRIOR to symptom onset What to Look for • Intense itching • Especially at night • Pimple-like itchy rash • May affect entire body OR Dermatologie.md common sites: • Wrist, elbow, armpit, webbing between the fingers, nipple, penis, waist, belt-line, and buttocks • Burrows (tunnels) may be seen on the skin • Tiny raised and crooked grayish-white or skin- colored lines Transmission • Direct, prolonged, skin-to-skin contact with an infested person • Sexual partners • Household members • Quick handshake/hug will usually not spread scabies How Long Do Mites Live? • 1-2 months on a person • 48-72 hours off a person • Scabies mites will die at 122 degrees for 10 minutes Webmd.com 5 Diagnosis • Customary appearance and distribution of the rash and presence of burrows. • Confirm diagnosis: • Obtain a skin scraping to examine under a microscope for mites, eggs, or mite fecal matter • Person can still be infested even if mites, eggs, or fecal matter cannot be found • Typically fewer than 10-15 mites present on the entire body • **Crusted scabies may be thousands of mites and should be considered highly contagious** How Do You Treat Scabies? 7 Treatment • Available only by prescription • No "over-the-counter“
    [Show full text]
  • 1 Wound Healing and Hyper-Hydration
    University of Huddersfield Repository Ousey, Karen and Cutting, Keith Wound healing and hyper-hydration - a counter intuitive model Original Citation Ousey, Karen and Cutting, Keith (2016) Wound healing and hyper-hydration - a counter intuitive model. Journal of wound care, 25 (2). pp. 68-75. ISSN 0969-0700 This version is available at http://eprints.hud.ac.uk/id/eprint/27031/ The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided: • The authors, title and full bibliographic details is credited in any copy; • A hyperlink and/or URL is included for the original metadata page; and • The content is not changed in any way. For more information, including our policy and submission procedure, please contact the Repository Team at: [email protected]. http://eprints.hud.ac.uk/ Wound healing and hyper‐hydration ‐ a counter intuitive model Abstract: Winters seminal work in the 1960s relating to providing an optimal level of moisture to aid wound healing (granulation and re‐epithelialisation) has been the single most effective advance in wound care over many decades. As such the development of advanced wound dressings that manage the fluidic wound environment have provided significant benefits in terms of healing to both patient and clinician.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • The Role of Carbonic Anhydrase in the Modulation of Central
    THE ROLE OF CARBONIC ANHYDRASE IN THE MODULATION OF CENTRAL RESPIRATORY-RELATED PH/CO2 CHEMORECEPTOR-STIMULATED BREATHING IN THE LEOPARD FROG (RANA PIPIENS) FOLLOWING CHRONIC HYPOXIA AND CHRONIC HYPERCAPNIA by Kajapiratha Srivaratharajah A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Cell and Systems Biology (Zoology) University of Toronto © Copyright by Kajapiratha Srivaratharajah (2008) The Role of Carbonic Anhydrase in the Modulation of Central Respiratory-Related pH/CO2 Chemoreceptor-Stimulated Breathing in the Leopard Frog (Rana pipiens) Following Chronic Hypoxia and Chronic Hypercapnia Kajapiratha Srivaratharajah Master of Science Graduate Department of Cell and Systems Biology University of Toronto 2008 ABSTRACT The aim of this thesis was to elucidate the role of carbonic anhydrase (CA) in the modulation of central pH/CO2-sensitive fictive breathing (measured using in vitro brainstem-spinal cord preparations) in leopard frogs (Rana pipiens) following exposure to chronic hypercapnia (CHC) and chronic hypoxia (CH). CHC caused an augmentation in fictive breathing compared to the controls (normoxic normocapnic). Addition of acetazolamide (ACTZ), a cell-permeant CA inhibitor, to the superfusate reduced fictive breathing in the controls and abolished the CHC- induced augmentation of fictive breathing. ACTZ had no effect on preparations taken from frogs exposed to CH. Addition of bovine CA to the superfusate did not alter fictive breathing in any group, suggesting that the effects of ACTZ were due to inhibition of intracellular CA. Taken together, these results indicate that CA is involved in central pH/CO2 chemoreception and the CHC-induced increase in fictive breathing in the leopard frog.
    [Show full text]
  • CCA Senior Care Options Formulary
    Commonwealth Care Alliance Senior Care Option HMO SNP 2021 List of Covered Drugs Formulary 30 Winter Street • Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 08/01/2021. For more recent information or other questions, please contact Senior Care Options Program (HMO SNP) Member Services, at 1-866-610-2273 or, for TTY users, 711, 8 a.m. – 8 p.m., 7 days a week, or visit www.commonwealthcaresco.org. HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Senior Care Options Program (HMO SNP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DO CUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Commonwealth Care Alliance. When it refers to “plan” or “our plan,” it means 2021 Senior Care Options Program. This document includes list of the drugs (formulary) for our plan which is current as of 08/01/2021. This formulary document applies to all SCO members. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy n etwork, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.
    [Show full text]
  • How to Deal with Distressingly Dry Skin? — by Melissa Raue, PA-C How to Deal with Distressingly Dry Skin?
    How To Deal With Distressingly Dry Skin? — By Melissa Raue, PA-C How To Deal With Distressingly Dry Skin? During the winter, some people’s skin often gets so dry that it flakes, cracks, or even bleeds. What can they do? Should they wash more or less often? Apply more moisturizer? Here are several preventive measures that will keep you comfortable and out of the doctor’s office. 1 Bathe daily. A 5-10 minute warm bath or shower adds moisture to the skin. Longer or hotter showers remove moisture and wash away natural protective oils. Close the 2 bathroom door. When taking that bath or shower, keep the door to the bathroom shut. This keeps the much-needed humidity in the room. Use a mild cleanser. 3 Deodorant bars, fragrance in soaps, and products containing alcohol strip natural oils from the skin, which dries the skin. Gently pat the skin dry. 4 Rubbing hard removes moisture and irritates sensitive dry skin. 5 Apply moisturizer within 3 minutes of getting out of the bath or shower. Many people think that moisturizer adds moisture to the skin. This is incorrect! Moisturizer traps existing water in the skin, preventing the water from evaporating. Moisturize 6 again if you need to! If skin is noticeably dry and uncomfortable, moisturizing more frequently throughout the day can help the skin heal. And will help prevent dry skin from returning. Ointments and creams will be more effective than lotions. Choose your moisturizer 7 by ingredients, not price. Moisturizer does not need to be expensive to be effective.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • Fagron Advanced Derma Compatibility Table
    Fagron Advanced Derma Compatibility table Legend Skin types Compatible combination for Oily skin Balanced skin Dehydrated skin Very dehydrated skin Affected skin Specific skin area 14/15 days 30 days 60 days OCCLUVAN™ EMOLIVAN™ VERSATILE™ VERSATILE™ NOURIVAN™ FITALITE™ NOURILITE™ SERAQUA™ NOURISIL™ SOLYDRA™ ESPUMIL™ RICH ANTIOX 90 days Especially recommended combination Compatible combination up to x% Combination not studied Combination not compatible API/DCI concentration(s) Common Aloe Vera Extract 0.5 to 10% 8% 5% Alpha Bisabolol 0.5 to 5% 1% 1% Ammonium Lactate 1 to 12% 10% 10% 8% Anthralin/Dithranol 0.05 to 3% Arginine Hydrochloride 2.5% Ascorbic Acid (Vitamin C) 5 to 15% 5% 10% Azelaic Acid 10 to 20% Benzoyl Peroxide 2.5 to 10% 5% Benzyl Benzoate 25% Betamethasone Dipropionate 0.05% Betamethasone Valerate 0.025 to 0.1% 0.05% Caffeine 1 to 2% Chamomile Extract 0.5 to 5% Ciclopirox Olamine 1% Clindamycin Hydrochloride 1 to 3% Clobetasol Propionate 0.05% Clotrimazole 1 to 2% Coal Tar Crude (Pix Lithanthracis) 1 to 10% Coal Tar Solution (Liquor Carbonis 5 to 20% Detergens) 10% 10% 10% Cyanocobalamin (Vitamin B12) 0.07% Desonide 0.05 to 0.1% Desoximetasone 0.25% Dexpanthenol 0.5 to 5% Diclofenac Sodium 3% Erythromycin 0.5 to 4% Finasteride 0.1% Fluocinolone Acetonide 0.01 to 0.1% Glycerol 0.5 to 20% 8% 5% Glycolic Acid 5 to 15% Hyaluronic Acid Sodium 0.2 to 2.5% Hydrocortisone 0.25 to 2.5% Hydrocortisone Acetate 0.25 to 2.5% Hydroquinone 2 to 4% Ketoconazole 2% Kojic Acid 1 to 4% Lactic Acid 1 to 20% 10% Lidocaine 0.5 to 10% 5% Lidocaine
    [Show full text]